Tesamorelin for Fat Loss: The Only FDA-Approved GH Peptide for Body Composition

Tesamorelin for Fat Loss: The Only FDA-Approved GH Peptide for Body Composition

Key Takeaways:

• Tesamorelin (brand name Egrifta) is FDA-approved for reducing visceral adipose tissue (VAT) in HIV-positive adults with lipodystrophy.
• It is the only GH-related peptide with FDA approval specifically for a body composition indication.
• Clinical trials show statistically significant visceral fat reduction (approximately 15-20% over 6 months) compared to placebo.
• Off-label interest for non-HIV visceral fat reduction is significant, but this use is not FDA-sanctioned.
• Like all GH secretagogues, tesamorelin elevates GH and IGF-1 with associated benefits and risks.

Important: This is not medical advice. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy. Any use outside this indication is off-label and should only be undertaken under physician supervision. This content summarizes published research for educational purposes. See our full medical disclaimer.

---

What is tesamorelin?

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) engineered by Theratechnologies Inc. It differs from the other GHRH analogs discussed on this site, like CJC-1295 and sermorelin, in one critical way: it has FDA approval for a body composition endpoint.

Tesamorelin (brand name Egrifta, later Egrifta SV) received FDA approval in 2010 for the reduction of excess abdominal fat in HIV-positive adults with lipodystrophy, a condition where antiretroviral therapy causes abnormal fat accumulation, particularly in the visceral (deep abdominal) compartment. For an overview of where tesamorelin fits within GH secretagogue research overall, see our growth hormone secretagogues guide.

The FDA approval of tesamorelin is significant for the broader GH peptide discussion because it provides the most rigorous human clinical trial data we have on what a GHRH analog can actually do to visceral fat in humans.

How tesamorelin works

Tesamorelin's mechanism is identical in principle to other GHRH analogs. It binds to the GHRH receptor on somatotroph cells in the anterior pituitary, triggering GH release through the cAMP/PKA signaling pathway. The result is increased GH secretion in a more physiologically pulsatile pattern, followed by downstream elevation of IGF-1.

What makes tesamorelin structurally distinct is a trans-3-hexenoic acid modification that extends its stability and half-life compared to native GHRH, though its duration of action is shorter than CJC-1295 with DAC. It is typically administered once daily as a subcutaneous injection.

GH then acts directly on adipose tissue. GH receptors are expressed in fat cells, and GH activation promotes lipolysis, the breakdown of stored triglycerides into free fatty acids for energy use. Visceral fat appears to be particularly responsive to GH-driven lipolysis compared to subcutaneous fat.

What the FDA trials showed

The tesamorelin approval was based on two Phase III randomized controlled trials (PMID: 20395564). These trials enrolled HIV-positive adults with confirmed lipodystrophy and measured outcomes at 26 weeks.

Primary outcomes: visceral fat reduction

Both trials demonstrated statistically significant reductions in visceral adipose tissue measured by CT scan in the tesamorelin groups compared to placebo.

Key findings across both trials:

• Visceral fat reduction of approximately 15-20% from baseline in the tesamorelin groups
• Placebo groups showed minimal change or slight increase in visceral fat
• The between-group difference was statistically significant (p < 0.001)
• Treatment effect was consistent across subgroups

After 26 weeks, subjects who discontinued tesamorelin and switched to placebo showed partial reversal of visceral fat reductions, suggesting the effect requires ongoing treatment to maintain.

Secondary outcomes

Beyond the primary visceral fat endpoint, the trials captured several secondary measures:

• Trunk-to-limb fat ratio improved in the tesamorelin group (less abdominal fat relative to limb fat)
• Waist circumference decreased by approximately 2-3 cm compared to placebo
• No significant changes in total body weight between groups (visceral fat loss was offset somewhat by other tissue changes)
• IGF-1 levels increased significantly, confirming the GH-stimulating mechanism was active
• Fasting glucose and insulin sensitivity: no significant worsening compared to placebo in the controlled trial, though this required monitoring

What the trials did not show

Total body weight did not change dramatically. Tesamorelin did not produce meaningful changes in subcutaneous fat in these trials. The effect was specific to visceral adipose tissue.

Lipid profiles showed some improvement (reduced triglycerides) but mixed results on other markers. The trials were not powered to show cardiovascular outcomes.

Off-label use: the non-HIV population

The clinical data from tesamorelin trials has generated significant interest for off-label use in people without HIV who have excess visceral fat, including those with metabolic syndrome, NAFLD/MASH, or general abdominal obesity.

The rationale is direct. The mechanism by which tesamorelin reduces visceral fat in HIV lipodystrophy, stimulating GH-driven lipolysis of visceral adipocytes, does not require HIV infection to be present. Excess visceral fat responds to GH stimulation regardless of cause. Some practitioners prescribe tesamorelin off-label for this indication.

What is known from the HIV trials provides a reasonable foundation for understanding what might be expected. Visceral fat reduction appears to be a genuine, measurable effect of GHRH-driven GH elevation. The magnitude (15-20% reduction over 6 months) is clinically meaningful but not dramatic.

For comparison, GLP-1 receptor agonists like semaglutide produce larger total body weight reductions and appear to reduce visceral fat more substantially, though through entirely different mechanisms (appetite suppression vs. GH-driven lipolysis). These are not equivalent interventions.

Comparison to other GH secretagogues

Tesamorelin sits in an interesting position within the GH secretagogue landscape. It has more clinical evidence than any other compound in the class for body composition, but its FDA approval restricts its on-label use to a specific population.

vs Sermorelin: Both are GHRH analogs with similar mechanisms. Tesamorelin has superior clinical trial data. Sermorelin has a longer history of physician use and compounding pharmacy availability. Their pharmacokinetics differ, with tesamorelin having a somewhat longer half-life than sermorelin but shorter than CJC-1295 with DAC.

vs CJC-1295: CJC-1295 (with DAC) has a much longer half-life and requires less frequent dosing. The body composition research on CJC-1295 is extrapolated from GH physiology and from the tesamorelin trials rather than from direct CJC-1295 body composition trials. Tesamorelin has the superior evidence base.

vs exogenous HGH: Tesamorelin preserves pulsatility and natural GH feedback regulation. Exogenous HGH bypasses these mechanisms. For a full comparison, see our GH secretagogues vs HGH guide.

Dosing

FDA-approved dosing for HIV lipodystrophy:

• 2 mg subcutaneous injection once daily
• Administered into the abdomen
• Rotate injection sites within the abdominal area
• Reconstituted from lyophilized powder immediately before injection

Off-label protocols reported in clinical contexts: Some practitioners prescribing off-label use similar dosing (1-2 mg daily). The clinical trial dose of 2 mg daily provides the reference point for dose selection.

Duration: The FDA trials ran 26 weeks. Off-label protocols vary, with some practitioners using 3-6 month courses. Fat loss from tesamorelin does not appear to plateau immediately, suggesting extended courses may produce progressive benefit, though this has not been studied long-term outside of HIV-specific research.

Timing: Like other GH secretagogues, tesamorelin is typically administered in a fasted state or before sleep to minimize insulin-driven blunting of GH secretion.

Side effects

Tesamorelin's FDA approval and the associated clinical trials provide better-characterized side effect data than most research peptides.

Fluid retention. Edema (swelling), particularly in the extremities, was the most commonly reported adverse event in the trials. This is consistent with GH-driven fluid retention.

Arthralgias (joint pain). Joint pain was reported at higher rates in the tesamorelin groups than placebo. This is a known effect of GH elevation.

Myalgias (muscle pain). Muscle aches reported in some subjects.

Peripheral neuropathy. Tingling or numbness in hands and feet, consistent with GH-driven fluid effects.

Injection site reactions. Redness, erythema, or irritation at the injection site.

Glucose metabolism. GH can cause insulin resistance, particularly with chronic elevation. The FDA trials did not show significant worsening of glucose tolerance at the population level, but fasting glucose increased in some subjects. People with diabetes or prediabetes require careful monitoring if using tesamorelin.

IGF-1 elevation. Tesamorelin significantly elevates IGF-1. The same long-term considerations around IGF-1 and cancer risk that apply to other GH secretagogues apply here.

Headache, nausea, vomiting. Reported in small percentages of trial subjects.

Contraindications and precautions

The FDA label for tesamorelin includes important contraindications:

• Active malignancy (cancer) or suspected malignancy
• Disruption of hypothalamic-pituitary axis (recent pituitary surgery, head trauma, radiation)
• Pregnancy
• Known hypersensitivity to tesamorelin or its components

IGF-1 elevation is not desirable in the context of active or suspected cancer. This is a fundamental consideration for anyone evaluating any GH secretagogue, including tesamorelin.

Monitoring parameters

For on-label use and for any supervised off-label use, key monitoring parameters include:

• IGF-1 levels (baseline and periodic)
• Fasting glucose and HbA1c (particularly in those with metabolic risk)
• Visceral fat assessment (CT or DEXA if available)
• Symptom assessment for edema, joint pain, neuropathy

FAQ

Is tesamorelin available for non-HIV patients? Tesamorelin is only FDA-approved for HIV-associated lipodystrophy. A physician can prescribe it off-label for other indications, but insurance will not cover it for off-label use. Out-of-pocket costs for Egrifta are substantial.

How does tesamorelin compare to GLP-1 drugs for visceral fat? GLP-1 receptor agonists like semaglutide produce larger total weight loss and are associated with meaningful visceral fat reduction, though primarily driven by caloric restriction from appetite suppression. Tesamorelin works through GH-driven lipolysis without appetite suppression. The mechanisms are not mutually exclusive, and some practitioners use both.

Does tesamorelin affect total body weight significantly? The clinical trials showed minimal change in total body weight compared to placebo. Visceral fat decreased while lean mass was maintained or mildly increased, roughly offsetting on the scale. Patients often report improved body shape and waist circumference despite minimal scale changes.

Can tesamorelin be stacked with GHRPs like ipamorelin? Theoretically yes, on the same dual-pathway rationale as other GHRH + GHRP stacks. However, this combination has not been studied in clinical trials. Stacking increases GH output, which also amplifies potential side effects.

What happens when you stop tesamorelin? The HIV trials showed partial reversal of visceral fat reductions after discontinuation. The treatment effect appears to be maintenance-dependent. This is consistent with the way GH influences fat metabolism: the drug creates a favorable hormonal environment for fat utilization, but that environment disappears when the drug is stopped.

---

Sources

1. Falutz J, et al. Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. 2010;304(4):392-400. PMID: 20395564
2. Stanley TL, et al. Tesamorelin decreases liver fat and liver enzymes in HIV-infected patients with mild to moderate liver disease. J Clin Endocrinol Metab. 2014. PMID: 24423330
3. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28586565
4. Grinspoon SK, et al. Long-term treatment with tesamorelin, a growth hormone-releasing factor analog, improves body composition parameters in HIV-infected patients with excess abdominal fat. J Acquir Immune Defic Syndr. 2012. PMID: 22481606
5. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID: 16984982

---

This content is for educational purposes only. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy. Off-label use should only occur under physician supervision. Full disclaimer.